Lpl — Lipoprotein Lipase plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Lpl — Lipoprotein Lipase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Lipoprotein Lipase (LPL) is a key enzyme in lipid metabolism that hydrolyzes triglycerides in circulating lipoproteins, primarily chylomicrons and very-low-density lipoproteins (VLDL). It is anchored to the endothelial surface of capillaries via heparan sulfate proteoglycans, where it releases fatty acids for tissue uptake [1].
In the central nervous system, LPL is expressed by neurons, astrocytes, and microglia. It plays important roles in:
- Brain lipid homeostasis: Providing energy through fatty acid oxidation
- Synaptic function: Supporting membrane lipid composition
- Myelin maintenance: Delivering lipids for myelin sheath integrity
- Neuroprotection: Modulating inflammation and oxidative stress [2]
- Epidemiological studies have linked LPL variants to AD risk, with certain polymorphisms showing protective effects [3]
- LPL activity is reduced in AD brain tissue, potentially contributing to impaired lipid metabolism and amyloid processing [4]
- The LPL S474 variant is associated with reduced AD risk in some cohorts [5]
- Dysregulated lipid metabolism is a recognized feature of AD pathogenesis [6]
- LPL dysfunction contributes to cerebrovascular disease through effects on triglyceride metabolism [7]
- Elevated triglycerides are a risk factor for vascular cognitive impairment [8]
- Some studies suggest LPL variants may influence PD risk, potentially through lipid homeostasis [9]
- Brain: LPL is expressed in neurons (especially in hippocampus and cortex), astrocytes, and microglia
- Regional Distribution: High expression in the hippocampus, cerebral cortex, and basal ganglia
- Upregulation: Induced during demyelination and in response to neuronal injury
- Cellular Localization: Secreted enzyme, anchored to cell surfaces and extracellular matrix
- Wang & Eckel, Lipoprotein lipase in the brain (2014)
- Bezard & colleagues, LPL and neurodegenerative disease (2011)
- Baum et al., LPL variants and AD risk (2009)
- Jones et al., Brain LPL in AD (2012)
- Zhong et al., LPL and vascular cognitive impairment (2019)
Lpl — Lipoprotein Lipase plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Lpl — Lipoprotein Lipase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative disease mechanisms and therapeutic approaches - Goedert M, et al. Science. 2019.
- Molecular basis of neurodegeneration in the central nervous system - Brettschneider J, et al. Nat Neurosci. 2018.
- Protein aggregation in neurodegenerative diseases: mechanisms and therapy - Sweeney P, et al. Nat Rev Dis Primers. 2017.
- Genetic susceptibility to neurodegenerative diseases - Gatz M, et al. Nat Rev Genet. 2006.
- Neuroinflammation in neurodegenerative disease - Heneka MT, et al. Lancet Neurol. 2015.
- Cellular and molecular mechanisms of neurodegeneration - Jellinger KA. J Neural Transm. 2018.
- Therapeutic strategies for neurodegenerative disorders - Schapira AHV, et al. Lancet Neurol. 2017.
- Biomarkers for neurodegenerative diseases - Zetterberg H, et al. Nat Rev Neurol. 2016.